VIEWS: 19 PAGES: 3 CATEGORY: Medicine POSTED ON: 5/30/2010
Protein A gained significant popularity among the producers of biotherapeutics due to its universal binding capacity. The high price of such affinity media precludes their adaptation to a single-use environment. Upfront's mixed mode ligand Rhobust MAbDirect MM provides an alternative to Protein A that helps to address these challenges. Experimental tests were conducted by Upfront Chromatography and DSM Biologies to determine the performance of the ligand during crude feedstock processing.
strap goes here purification www.pharma-mag.com robust soLution for DoWnstream ProCessing of biotHeraPeutiCs Faced with tremendous cost pressures, the biomanufacturing in
Pages to are hidden for
"ROBUST SOLUTION FOR DOWNSTREAM PROCESSING OF BIOTHERAPEUTICS"Please download to view full document